These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 29954816)

  • 21. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
    Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
    Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist.
    De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H
    Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional age-related changes of neuromelanin and iron in the substantia nigra based on neuromelanin accumulation and iron deposition.
    Chen Y; Gong T; Sun C; Yang A; Gao F; Chen T; Chen W; Wang G
    Eur Radiol; 2023 May; 33(5):3704-3714. PubMed ID: 36680605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific visualization of neuromelanin-iron complex and ferric iron in the human post-mortem substantia nigra using MR relaxometry at 7T.
    Lee H; Baek SY; Chun SY; Lee JH; Cho H
    Neuroimage; 2018 May; 172():874-885. PubMed ID: 29162523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism.
    Zhao XJ; Niu XY; You HY; Zhou M; Ji XB; Liu Y; Wu L; Ding XL
    Curr Med Sci; 2019 Oct; 39(5):831-835. PubMed ID: 31612404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy.
    Miyoshi F; Ogawa T; Kitao SI; Kitayama M; Shinohara Y; Takasugi M; Fujii S; Kaminou T
    AJNR Am J Neuroradiol; 2013; 34(11):2113-8. PubMed ID: 23744697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microstructural abnormalities of substantia nigra in Parkinson's disease: A neuromelanin sensitive MRI atlas based study.
    Safai A; Prasad S; Chougule T; Saini J; Pal PK; Ingalhalikar M
    Hum Brain Mapp; 2020 Apr; 41(5):1323-1333. PubMed ID: 31778276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
    He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
    Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease.
    Du G; Lewis MM; Styner M; Shaffer ML; Sen S; Yang QX; Huang X
    Mov Disord; 2011 Aug; 26(9):1627-32. PubMed ID: 21618607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI).
    Nam Y; Gho SM; Kim DH; Kim EY; Lee J
    J Magn Reson Imaging; 2017 Aug; 46(2):528-536. PubMed ID: 27859983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
    Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
    Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Ofori E; Krismer F; Burciu RG; Pasternak O; McCracken JL; Lewis MM; Du G; McFarland NR; Okun MS; Poewe W; Mueller C; Gizewski ER; Schocke M; Kremser C; Li H; Huang X; Seppi K; Vaillancourt DE
    Mov Disord; 2017 Oct; 32(10):1457-1464. PubMed ID: 28714593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.
    Xing Y; Sapuan A; Dineen RA; Auer DP
    Mov Disord; 2018 Nov; 33(11):1792-1799. PubMed ID: 30423212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease.
    Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Liu T; Wang Y; Tomiyama N
    Br J Radiol; 2018 Jun; 91(1086):20180037. PubMed ID: 29498540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroimaging in Parkinson's disease: focus on substantia nigra and nigro-striatal projection.
    Frosini D; Cosottini M; Volterrani D; Ceravolo R
    Curr Opin Neurol; 2017 Aug; 30(4):416-426. PubMed ID: 28537985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.